Russell Nichols

Safety and efficacy of galcanezumab in patients for whom previous migraine preventive medication from two to four categories had failed (CONQUER): a multicentre, randomised, double-blind, placebo-controlled, phase 3b trial

Wim M. Mulleners, Byung‐Kun Kim, Miguel J. A. Láinez et al. · The Lancet Neurology · 2020 · 283 citations

Pharmacy, Pharmacology, Pharmacotherapy +10

Evaluation of the impact of Chernobyl on the prevalence of congenital anomalies in 16 regions of Europe. EUROCAT Working Group

Helen Dolk, Russell Nichols · International Journal of Epidemiology · 1999 · 65 citations · Full text

Public Health, Obstetrics, Epidemiology +16

Galcanezumab in Patients with Multiple Previous Migraine Preventive Medication Category Failures: Results from the Open-Label Period of the CONQUER Trial

Uwe Reuter, Christian Lucas, David Doležil et al. · Advances in Therapy · 2021 · 37 citations · Full text

Pharmacy, Pharmacology, Pharmacotherapy +15

Analysis of Initial Nonresponders to Galcanezumab in Patients With Episodic or Chronic Migraine: Results From the EVOLVE‐1, EVOLVE‐2, and REGAIN Randomized, Double‐Blind, Placebo‐Controlled Studies

Russell Nichols, Erin Doty, Sara Sacco et al. · Headache The Journal of Head and Face Pain · 2018 · 28 citations · Full text

Pharmacy, Pharmacology, Pharmacotherapy +12

A real-world analysis of patient-reported outcomes in patients with migraine by preventive treatment eligibility status in the US and Europe

Janet H. Ford, Shonda A. Foster, Russell Nichols et al. · Journal of Patient-Reported Outcomes · 2020 · 26 citations · Full text

Pharmacy, Neurology, Preventive Medicine +17